Melanocortin 1 receptor agonists reduce proteinuria.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2010-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1681/ASN.2009101025PMID 20507942PMCID PMC2938589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Membranous nephropathy.

  2011cited by this paper
• M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

  2009cited by this paper
• Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24.

  2009cited by this paper
• Membranous nephropathy

  2008cited by this paper
• The melanocortin system in leukocyte biology

  2007cited by this paper
• EXPERIMENTAL GLOMERULONEPHRITIS

  2007cited by this paper
• Membranous nephropathy.

  2007cited by this paper
• A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.

  2006cited by this paper
• Primary human glomerular endothelial cells produce proteoglycans, and puromycin affects their posttranslational modification.

  2005cited by this paper
• Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review.

  2004cited by this paper
• Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation

  2004cited by this paper
• ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy.

  2004cited by this paper
• ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses.

  2004cited by this paper
• Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes.

  2003cited by this paper
• Redundancy of a Functional Melanocortin 1 Receptor in the Anti-inflammatory Actions of Melanocortin Peptides: Studies in the Recessive Yellow (e/e) Mouse Suggest an Important Role for Melanocortin 3 Receptor1

  2003cited by this paper
• Mechanisms involved in the side effects of glucocorticoids.

  2002cited by this paper
• Effect of combining ACE inhibitor and statin in severe experimental nephropathy.

  2002cited by this paper
• A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression.

  2002cited by this paper
• New highly specific agonistic peptides for human melanocortin MC(1) receptor.

  2000cited by this paper
• Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.

  1999cited by this paper
• Expression of the MC1 receptor gene in normal and malignant human melanocytes. A semiquantitative RT-PCR study.

  1999cited by this paper
• Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands.

  1998cited by this paper
• Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.

  1998cited by this paper
• Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis.

  1996cited by this paper
• Distribution of cDNA for melanocortin receptor subtypes in human tissues.

  1996cited by this paper
• A review of therapeutic studies of idiopathic membranous glomerulopathy.

  1995cited by this paper
• Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.

  1994cited by this paper
• Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues.

  1994cited by this paper
• Prognosis of untreated patients with idiopathic membranous nephropathy

  1993cited by this paper
• Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis.

  1993cited by this paper
• The cloning of a family of genes that encode the melanocortin receptors.

  1992cited by this paper
• Experimental glomerulonephritis.

  1988cited by this paper
• [38] Experimental glomerulonephritis

  1988cited by this paper
• A simple fluorometric assay for lipoperoxide in blood plasma.

  1976cited by this paper
• ACTH receptors in the adrenal: specific binding of ACTH-125I and its relation to adenyl cyclase.

  1970cited by this paper

• Kidney-targeted nanoplatforms: Strategies and applications

  2026cites this paper
• From MC1R to MC5R, a new horizon for the podoprotective effect of melanocortin.

  2025cites this paper
• Intercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy

  2025cites this paper
• Melanocortin 5 receptor signaling protects against podocyte injury in proteinuric glomerulopathies.

  2025cites this paper
• Resolution Pharmacology: State-of-the-art and therapeutic landscape

  2025cites this paper
• Melanocortins: A new paradigm in immunotherapy for membranous nephropathy.

  2025cites this paper
• Adrenocorticotropic hormone: Therapeutic use and effects in nephrotic syndrome

  2024cites this paper
• Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options

  2024cites this paper
• Enhanced Biohomogeneous Composite Membrane-Encapsulated Nanoplatform with Podocyte Targeting for Precise and Safe Treatment of Diabetic Nephropathy.

  2023cites this paper
• Negative Modulation of B Cell Activation by Melanocortin 1 Receptor Signaling Protects against Membranous Nephropathy

  2022cites this paper
• Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy.

  2022cites this paper
• Adrenocorticotropic Hormone: An Expansion of Our Current Understanding of the Treatment for Nephrotic Syndrome.

  2021cites this paper
• How immunosuppressive drugs may directly target podocytes in glomerular diseases

  2021cites this paper
• Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

  2021cites this paper
• Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation

  2021cites this paper
• Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities

  2021cites this paper
• Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model

  2020cites this paper
• ACTH Treatment for Management of Nephrotic Syndrome: A Systematic Review and Reappraisal

  2020cites this paper
• New Aspects of Pathogenesis and Treatment of Membranous Glomerulopathy After the MENTOR Study

  2020cites this paper
• IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

  2020cites this paper
• A case of relapsing immunoglobulin A nephropathy secondary to immunotherapy

  2020cites this paper
• Современные фармакологические подходы к лечению первичного нефротического синдрома

  2020cites this paper
• Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.

  2020cites this paper
• Melanocortin Receptor Agonist (Corticotrophin) in Treatment of Refractory Diabetic Nephropathy

  2020cites this paper
• Approach to the Patient with Chronic Glomerular Disease

  2020cites this paper
• The Use of ACTH Gel in Membranous Nephropathy

  2019cites this paper
• Adrenocorticotropic Hormone in the Treatment of Focal Segmental Glomerulosclerosis Following Kidney Transplantation.

  2019cites this paper
• Treatment of nephrotic syndrome: going beyond immunosuppressive therapy

  2019cites this paper
• Use of Repository Corticotropin Gel (Acthar) in Progressive Nephrotic Syndrome Secondary to Transplant Glomerulopathy: A Report of Three Cases

  2019influential citation
• Family Medicine and Primary Care : Open Access Case Report

  2019cites this paper
• An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression

  2019cites this paper
• Focal Segmental Glomerulosclerosis and the Role of ACTH

  2019cites this paper
• ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation

  2019cites this paper
• New strategies and perspectives on managing IgA nephropathy

  2019cites this paper
• Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis

  2018cites this paper
• Therapeutic Response of Natural Adrenocorotropin in Treatment of Proteinuria due to ANCA Negative Pauci-Immune Crescentic Glomerulonephritis

  2018cites this paper
• Treatment of primary membranous nephropathy: where are we now?

  2018cites this paper
• FSGS ACTH gel

  2018cites this paper
• Therapeutic Response of Repository Corticotropin Injection in Treatment of Proteinuria Due to Anca Negative Pauci-immune Crescentic Glomerulonephritis.

  2018cites this paper
• Does What Goes Around Always Come Around?

  2018cites this paper
• Use of synthetic adrenocorticotropic hormone in patients with IgA nephropathy

  2018cites this paper
• New Aspects on Pathogenesis and Treatment of Membranous Glomerulopathy

  2018cites this paper
• Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis

  2018cites this paper
• FSGS ACTH Gel: Part of the Answer?

  2018cites this paper
• Therapy for Proliferative Lupus Nephritis.

  2018cites this paper
• Advanced therapeutics in focal and segmental glomerulosclerosis

  2018cites this paper
• Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization

  2018cites this paper
• Investigational drugs in development for focal segmental glomerulosclerosis

  2017cites this paper
• Principles of Biology: Biology 211, 212, and 213

  2017cites this paper
• Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy

  2017cites this paper
• Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor

  2017cites this paper
• Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series

  2016cites this paper
• Minimal Change Disease

  2016cites this paper
• Melanocortin-1 Receptor-Stimulation and its Downstream Effector Mechanisms in Podocytes

  2016cites this paper
• cacy and safety of adrenocorticotropic hormone treatment in glomerular diseases : a systematic review and meta-analysis

  2016influential citation
• Membranous Nephropathy - Challenges in diagnostics and treatment

  2016cites this paper
• Adult idiopathic nephrotic syndrome: Prognosis, biomarkers and outcome

  2016cites this paper
• ACTH action on podocytes: mystery solved?

  2016cites this paper
• Proteinuria: Basic Mechanisms, Pathophysiology and Clinical Relevance

  2016cites this paper
• Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis

  2016influential citation
• ACTH action on podocytes : mystery solved ? 11 12 13

  2016cites this paper
• Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.

  2016influential citation
• Pharmacological treatment of primary membranous nephropathy in 2016

  2016cites this paper
• Drug discovery in focal and segmental glomerulosclerosis.

  2016cites this paper
• MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy

  2016cites this paper
• The podocyte as a direct target for treatment of glomerular disease?

  2016cites this paper
• Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance

  2016influential citation
• Informing Clinical Practice in Nephrology

  2015cites this paper
• Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma

  2015cites this paper
• Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study

  2015cites this paper
• [In Process Citation].

  2015cites this paper
• Overview of Current and Alternative Therapies for Idiopathic Membranous Nephropathy

  2015cites this paper
• Novel therapies for FSGS: preclinical and clinical studies.

  2015cites this paper
• Induction of Proteinuria by Cannabinoid Receptors 1 Signaling Activation in CB1 Transgenic Mice

  2015cites this paper
• Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study

  2015cites this paper
• Management of Membranous Nephropathy in Western Countries

  2015cites this paper
• A review of the re-emergence of adrenocorticotrophic hormone therapy in glomerular disease, more than a drug of last resort?

  2015cites this paper
• Resistant nephrotic syndrome: review of trials using ACTH and a case series of six patients treated with ACTHar.

  2015cites this paper
• Podocyte Melanocortin 1 Receptor Mediated Signaling A potential new target for patients with kidney diseases

  2015cites this paper
• Membranous nephropathy in children

  2015cites this paper
• Primary Glomerular Disease Clinical Trials: A Critical Appraisal

  2015cites this paper
• 19 – Membranous Nephropathy

  2014cites this paper
• Glomerular diseases: membranous nephropathy--a modern view.

  2014cites this paper
• Alpha‐melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus‐like model

  2014cites this paper
• Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus

  2014cites this paper
• Immunomodulatory Drugs and the Podocyte

  2014cites this paper
• Performance-enhancing strategies for deceased donor kidneys

  2014cites this paper
• α-Melanocyte Stimulating Hormone Treatment in Pigs Does Not Improve Early Graft Function in Kidney Transplants from Brain Dead Donors

  2014cites this paper
• Melanocortin Peptides: Potential Targets in Systemic Lupus Erythematosus

  2014influential citation
• Body Pigmentation as a Risk Factor for the Formation of Intracranial Aneurysms

  2014cites this paper
• Leveraging melanocortin pathways to treat glomerular diseases.

  2014cites this paper
• Diagnostic tests and treatment options in glomerular disease: 2014 update.

  2014cites this paper
• Reduction of Proteinuria through Podocyte Alkalinization*

  2014influential citation
• A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy

  2014cites this paper
• Effects of Melanocortin 1 Receptor Agonists in Experimental Nephropathies

  2014influential citation
• Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotropic Hormone

  2013cites this paper
• The Podocyte as a Therapeutic Target in Proteinuric Kidney Disease

  2013cites this paper
• α-MSH Analogue Attenuates Blood Pressure Elevation in DOCA-Salt Hypertensive Mice

  2013cites this paper
• Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.

  2013cites this paper
• New perspectives on the melanocortins and their cardiovascular effects: Potential implications for the treatment of cardiovascular diseases with melanocortin analogues

  2013influential citation